Published in TB and Outbreaks Week, September 27th, 1999
Experiments were done to determine how an alteration of the treatment schedule of 5 or 32 mg/kg/day per os (p.o.) doses of GS 4104 [the ethyl ester prodrug of the neuraminidase inhibitor (3R, 4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-cylohexene-1-carboxylic acid (GS 4071)] would affect influenza A (H1N1) virus infection in mice ("Influence of Treatment Schedule and Viral Challenge Dose on the in vivo Influenza Virus-Inhibitory Effects of the Orally Administered Neuraminidase Inhibitor GS 4104," Antivir Chem...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week